CA3113472A1 - Cellular reprogramming to reverse aging and promote organ and tissue regeneration - Google Patents

Cellular reprogramming to reverse aging and promote organ and tissue regeneration Download PDF

Info

Publication number
CA3113472A1
CA3113472A1 CA3113472A CA3113472A CA3113472A1 CA 3113472 A1 CA3113472 A1 CA 3113472A1 CA 3113472 A CA3113472 A CA 3113472A CA 3113472 A CA3113472 A CA 3113472A CA 3113472 A1 CA3113472 A1 CA 3113472A1
Authority
CA
Canada
Prior art keywords
expression
nucleic acid
klf4
composition
oct4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3113472A
Other languages
English (en)
French (fr)
Inventor
David A. Sinclair
Yuancheng Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CA3113472A1 publication Critical patent/CA3113472A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CA3113472A 2018-09-28 2019-09-27 Cellular reprogramming to reverse aging and promote organ and tissue regeneration Pending CA3113472A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862738922P 2018-09-28 2018-09-28
US62/738,922 2018-09-28
US201962792283P 2019-01-14 2019-01-14
US62/792,283 2019-01-14
US201962865877P 2019-06-24 2019-06-24
US62/865,877 2019-06-24
US201962880488P 2019-07-30 2019-07-30
US62/880,488 2019-07-30
PCT/US2019/053545 WO2020069373A1 (en) 2018-09-28 2019-09-27 Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Publications (1)

Publication Number Publication Date
CA3113472A1 true CA3113472A1 (en) 2020-04-02

Family

ID=68281948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3113472A Pending CA3113472A1 (en) 2018-09-28 2019-09-27 Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Country Status (11)

Country Link
US (5) US12409207B2 (https=)
EP (1) EP3856226B1 (https=)
JP (2) JP7593639B2 (https=)
KR (1) KR20210068485A (https=)
CN (1) CN113453702A (https=)
AU (2) AU2019347666B2 (https=)
BR (1) BR112021004670A2 (https=)
CA (1) CA3113472A1 (https=)
IL (1) IL281470B2 (https=)
MX (1) MX2021003663A (https=)
WO (1) WO2020069373A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197421A1 (en) 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
CA3202332A1 (en) 2015-12-07 2017-06-15 Agex Therapeutics, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
CN110628821B (zh) * 2018-06-25 2022-02-18 首都医科大学宣武医院 一种细胞模型及其制备方法、应用
MX2021003663A (es) 2018-09-28 2021-05-28 Harvard College Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US20240207449A1 (en) * 2021-04-09 2024-06-27 Washington University Compositions and methods for treatment of crx-mediated retinopathies
CN114240934B (zh) * 2022-02-21 2022-05-10 深圳大学 一种基于肢端肥大症的图像数据分析方法及系统
US20230302044A1 (en) * 2022-03-28 2023-09-28 Steve Reilly Composition to increase cellularlongevity
CN114622020B (zh) * 2022-03-30 2022-09-27 华南农业大学 一种与鸡生长性状相关的klhl31基因分子标记及应用
JP2025511883A (ja) 2022-04-06 2025-04-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 中枢神経系の加齢を逆行させること
JP2025513861A (ja) * 2022-04-15 2025-04-30 ロノ ジェヤク インコーポレイテッド 老化細胞の若返りまたは細胞老化の遅延または防止用組成物
WO2024012502A1 (zh) * 2022-07-12 2024-01-18 南京瑞初医药有限公司 组合物及其使用方法
CN119562824A (zh) * 2022-07-12 2025-03-04 南京瑞初医药有限公司 组合物及其使用方法
CN119546324A (zh) * 2022-07-12 2025-02-28 南京瑞初医药有限公司 组合物及其使用方法
EP4558610A2 (en) * 2022-07-19 2025-05-28 Syntax Bio, Inc. Systems for stem cell programming and methods thereof
EP4593855A1 (en) * 2022-09-28 2025-08-06 Altos Labs, Inc. Expression of regeneration factors in aged/senescent cells
CN115607689A (zh) * 2022-10-13 2023-01-17 呈诺再生医学科技(北京)有限公司 Klf7基因在制备逆转细胞衰老的药物中的应用
CN116041477B (zh) * 2022-10-13 2023-08-08 呈诺再生医学科技(北京)有限公司 Tdgf1基因在制备治疗衰老相关疾病或逆转细胞衰老的药物中的应用
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy
JP2026504911A (ja) * 2023-01-19 2026-02-10 アルトス ラブス，インコーポレーテッド 臓器移植における再生因子の使用
WO2024226169A2 (en) * 2023-04-24 2024-10-31 The Schepens Eye Research Institute, Inc. Methods of preserving vision and treating vision loss
WO2024233791A1 (en) * 2023-05-11 2024-11-14 Seelos Therapeutics, Inc. Methods of treating neurodegenerative disorders
CN119265241A (zh) * 2023-06-30 2025-01-07 深圳菁童生命科学有限公司 一种无相分离转录因子介导启始阶段重编程使细胞年轻化的方法
CN116555432B (zh) * 2023-07-05 2023-09-05 广州凯普医药科技有限公司 一种膀胱癌快速检测试剂盒
KR20260040009A (ko) * 2023-07-11 2026-03-23 난징 레주 테라퓨틱스 컴퍼니 리미티드 조성물 및 이의 사용 방법
CN116898988A (zh) * 2023-08-15 2023-10-20 臻赫医药(杭州)有限公司 皮肤重编程因子制剂、生物材料及用途
CN117281925A (zh) * 2023-08-15 2023-12-26 臻赫医药(杭州)有限公司 皮肤重编程因子制剂在制备促皮肤伤口愈合药物中的用途
CN119792490A (zh) * 2023-10-10 2025-04-11 中国科学院动物研究所 增加oskm含量或活性的物质在预防关节软骨衰老及治疗骨关节炎疾病中的应用
WO2025213038A1 (en) * 2024-04-05 2025-10-09 Erik Berglund Systems and methods for kidney perfusion
WO2026024954A2 (en) * 2024-07-24 2026-01-29 Altos Labs, Inc. Use of regeneration factors in organ transplantation
CN118831181B (zh) * 2024-09-20 2025-02-11 江苏集萃药康生物科技股份有限公司 一种三突变阿尔兹海默症小鼠模型的构建方法及其应用
CN119280375A (zh) * 2024-09-24 2025-01-10 深圳市第二人民医院(深圳市转化医学研究院) Oct4、sox2、klf4和tert基因在制备抗衰老的药物中的应用

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
JPH09500526A (ja) 1993-06-14 1997-01-21 ベーアーエスエフ アクツィエンゲゼルシャフト テトラサイクリン反応性プロモーターによる真核細胞の遺伝子発現の厳密な制御
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU746850B2 (en) 1994-07-01 2002-05-02 Tet Systems Holding Gmbh & Co. Kg Tetracycline-regulated transcriptional modulaters
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5928941A (en) 1996-10-07 1999-07-27 President And Fellows Of Harvard College Repressor kruppel-like factor
DE19818620A1 (de) 1998-04-21 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Blase-Normal
DE19851415B4 (de) 1998-11-07 2010-11-04 Wolfgang Hillen Mutanter Transaktivator
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
US7364868B2 (en) 1999-05-19 2008-04-29 The Uab Research Foundation Krüppel-like transcriptional factor KLF4/GKLF and uses thereof
WO2000069450A1 (en) 1999-05-19 2000-11-23 The Uab Research Foundation Oncogene identification by transformation of rk3e cells and uses thereof
US20030138799A1 (en) 1999-05-19 2003-07-24 Ruppert J. Michael Oncogene identification by transformation of RK3E cells and uses thereof
AU783233B2 (en) 1999-06-07 2005-10-06 Tet Systems Holding Gmbh & Co. Kg Novel TET repressor-based transcriptional regulatory proteins
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
US20030165921A1 (en) 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
US20070042392A1 (en) 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1358349A2 (en) 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US20020165180A1 (en) 2000-09-18 2002-11-07 Zoe Weaver Process for identifying anti-cancer therapeutic agents using cancer gene sets
US20050064454A1 (en) 2000-06-05 2005-03-24 Young Paul E. Cancer gene determination and therapeutic screening using signature gene sets
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
CA2325088A1 (en) 2000-12-01 2002-06-01 Fusogenix Inc. Novel membrane fusion proteins derived from poikilothermic reovirus
US20030065157A1 (en) 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer
US20070060743A1 (en) 2001-05-16 2007-03-15 Tang Y Tom Novel nucleic acids and polypeptides
WO2003012113A2 (en) 2001-08-02 2003-02-13 Gencell S.A. Inducible expression systems employing ppar transcriptional activators
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
US20030186281A1 (en) 2001-12-21 2003-10-02 Wolfgang Hillen Modified tetracycline repressor protein compositions and methods of use
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP2006516192A (ja) 2002-10-18 2006-06-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004073657A2 (en) 2003-02-19 2004-09-02 Protein Design Labs, Inc. Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
WO2006023207A2 (en) 2004-08-19 2006-03-02 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Coacervate of anionic and cationic polymer forming microparticles for the sustained release of therapeutic agents
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
WO2006123930A2 (en) 2005-05-20 2006-11-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Nucleic acids and polypeptides that are useful in controlling neuronal regeneration
US20100190250A1 (en) * 2005-10-14 2010-07-29 Jifan Hu Methods of Rejuvenating Cells In Vitro and In Vivo
JP5155176B2 (ja) 2005-11-17 2013-02-27 ティーイーティー システムズ ゲーエムベーハー ウント ツェーオー． カーゲー 誘導発現系
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
WO2008100328A2 (en) * 2006-07-13 2008-08-21 Burnham Institute For Medical Research METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32
WO2008051854A2 (en) 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
US8080647B2 (en) 2006-11-22 2011-12-20 Pioneer Hi Bred International Inc Tetracycline repressor and uses thereof
WO2008081435A2 (en) 2006-12-29 2008-07-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for predicting prognosis of multiple sclerosis
US9243226B2 (en) 2007-02-23 2016-01-26 University Of Central Florida Research Foundation, Inc. Biasing of cells toward retinal, corneal or lens development
WO2008105630A1 (en) 2007-02-27 2008-09-04 Procell Therapeutics Inc. Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells
JP2010537629A (ja) 2007-08-30 2010-12-09 アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム 動脈形成に関与する経路及びその使用
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
WO2009067563A1 (en) 2007-11-19 2009-05-28 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
WO2009067757A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
AU2008329562A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Sox2 protein
EP2103685A1 (en) 2008-03-20 2009-09-23 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (iPS) cells using site-specific recombination
US20110061118A1 (en) 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CN101302553A (zh) 2008-05-30 2008-11-12 广州华峰生物科技有限公司 基于环介导等温扩增技术的结核分歧杆菌基因快速诊断试剂盒及其检测方法
EP3279314A1 (en) 2008-06-04 2018-02-07 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
EP3231869A1 (en) 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
US9127256B2 (en) 2008-07-16 2015-09-08 Dnavec Corporation Method for production of reprogrammed cell using chromosomally unintegrated virus vector
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
WO2010030003A1 (ja) 2008-09-12 2010-03-18 協和発酵キリン株式会社 細胞のリプログラミングに用いられる複数遺伝子の発現制御システム
US8636884B2 (en) 2008-09-15 2014-01-28 Abbott Diabetes Care Inc. Cationic polymer based wired enzyme formulations for use in analyte sensors
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
CA2688804A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production
JP2012513218A (ja) 2008-12-23 2012-06-14 ヴィヴォスクリプト，インコーポレイテッド 遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法
CN102439045A (zh) 2009-03-12 2012-05-02 株式会社普罗赛尔制药 利用可穿透细胞的重编程转录因子建立诱导性多能干细胞用于个性化干细胞疗法
KR20110134939A (ko) 2009-04-03 2011-12-15 더 맥클린 하스피털 코퍼레이션 유도된 다능성 줄기 세포
US10837020B2 (en) 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
US20100273220A1 (en) 2009-04-22 2010-10-28 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CN101993495B (zh) 2009-08-12 2013-07-24 上海近岸科技有限公司 一种蛋白质混合物及其制备方法
JP5514215B2 (ja) 2009-08-31 2014-06-04 国立大学法人大阪大学 口腔粘膜由来細胞を利用した誘導多能性幹細胞の効率的な製造方法
JP2013505232A (ja) 2009-09-16 2013-02-14 スティヒティング ヘット ネーデルラント カンカー インスティテュート 癌治療のための薬剤標的としてのＦｒａ−１標的遺伝子
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2011068916A1 (en) 2009-12-01 2011-06-09 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2011145615A1 (ja) 2010-05-18 2011-11-24 タカラバイオ株式会社 多能性幹細胞の製造のための核酸
GB201008267D0 (en) 2010-05-18 2010-06-30 Univ Edinburgh Cationic lipids
EP2388336A1 (en) 2010-05-19 2011-11-23 Signature Diagnostics AG Method and kits for diagnosing colorectal cancer
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
WO2012012708A1 (en) 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells
WO2012014207A2 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
CA2809515A1 (en) 2010-08-30 2012-03-08 Dnavec Corporation Composition for inducing pluripotent stem cell, and use thereof
AU2011305572B2 (en) 2010-09-20 2016-08-04 Diane Goll Microencapsulation process and product
WO2012040825A1 (en) 2010-09-29 2012-04-05 Innovascreen Inc. Recombinant polypeptides for membrane fusion and uses thereof
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2643459B1 (en) 2010-11-24 2017-09-27 Takara Bio USA, Inc. Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
CN103327970A (zh) 2010-11-26 2013-09-25 约翰内斯堡威特沃特斯兰德大学 聚合物-脂质纳米粒子的聚合基质作为药物剂型
KR101255338B1 (ko) 2010-12-15 2013-04-16 포항공과대학교 산학협력단 표적 세포에 대한 폴리뉴클레오티드 전달체
WO2012083017A2 (en) 2010-12-16 2012-06-21 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
DK2655621T3 (en) 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
US9228204B2 (en) 2011-02-14 2016-01-05 University Of Utah Research Foundation Constructs for making induced pluripotent stem cells
WO2012112603A1 (en) 2011-02-14 2012-08-23 University Of Utah Research Foundations Constructs and methods for generating induced pluri potent stem ( ips) cells
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
US8709466B2 (en) 2011-03-31 2014-04-29 International Business Machines Corporation Cationic polymers for antimicrobial applications and delivery of bioactive materials
JP6584776B2 (ja) * 2011-04-08 2019-10-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 細胞を幼若化するための方法
US10092660B2 (en) 2011-04-25 2018-10-09 Stc.Unm Solid compositions for pharmaceutical use
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
EP2710130B1 (en) 2011-05-19 2022-06-29 Fundación Pública Andaluza Progreso Y Salud Highly inducible dual-promoter lentiviral tet-on system
US9862926B2 (en) * 2011-06-27 2018-01-09 Cellscript, Llc. Inhibition of innate immune response
GB201118964D0 (en) 2011-11-03 2011-12-14 Ucl Business Plc Method
WO2013139429A1 (en) 2012-03-21 2013-09-26 Merck Patent Gmbh Induced neural stem cells
EP2836577B1 (en) 2012-04-11 2017-06-07 The Lubrizol Corporation Dispersants derived from hydroxy fatty acid polyesters and polyalkylene glycol dispersants
CN104508131B (zh) 2012-05-21 2018-11-23 加利福尼亚大学董事会 通过合成的自我复制的RNA形成人iPS细胞
WO2013177228A1 (en) 2012-05-22 2013-11-28 Loma Linda University Generation of integration/transgene-free stem cells
EP2669381A1 (en) 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
DK2898076T3 (en) 2012-09-19 2018-06-14 Dsm Ip Assets Bv METHOD OF CELL MODIFICATION USING ESSENTIAL GENES AS MARKERS AND EVEN RECYCLING THESE
CN104919048B (zh) * 2012-10-01 2018-10-26 台北荣民总医院 制备诱导多能干细胞的方法及其应用
EP2907870A4 (en) 2012-10-09 2016-04-06 Hayashi Nakanobu REPROGRAMMING OF PEPTIDES AND USE THEREOF
KR20150087321A (ko) 2012-11-21 2015-07-29 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소 생물학적 활성의 결정을 위한 수단 및 방법
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
WO2014152607A2 (en) 2013-03-14 2014-09-25 University Of Massachusetts Dosage compensating transgenes and cells
EP3003350B1 (en) 2013-05-27 2018-02-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Targeted modulation of macrophages
US10076574B2 (en) 2013-10-25 2018-09-18 Wayne State University Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
WO2015077498A1 (en) 2013-11-20 2015-05-28 The University Of North Carolina At Chapel Hill Methods and compositions for treating disorders of the eye
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3194623B1 (en) 2014-08-12 2022-01-05 Wayne State University Systems and methods to detect stem cell stress and uses thereof
KR101663811B1 (ko) 2015-04-20 2016-10-11 연세대학교 산학협력단 뇌신경 질환의 예방 또는 치료용 약제학적 조성물
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
US10428307B2 (en) 2015-04-29 2019-10-01 The Catholic University Of Korea Industry-Academic Cooperation Foundation Method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors
EP3298141A4 (en) 2015-05-17 2019-01-09 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP3334755B1 (en) 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
AU2016315703A1 (en) 2015-08-31 2018-03-08 The Trustees Of The University Of Pennsylvania Chimeric AAV-anti-VEGF for treating cancer in canines
US10429378B2 (en) * 2015-09-15 2019-10-01 Board Of Supervisors Of Louisiana State University Methods of differentiating preadipocytes and uses thereof
WO2017173354A2 (en) 2016-04-01 2017-10-05 University Of Iowa Research Foundation METABOLICALLY STABILIZED DOUBLE STRANDED mRNA
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US20190194756A1 (en) 2016-09-02 2019-06-27 Ruprecht-Karls-Universität Heidelberg Gene panel specific for pulmonary hypertension and its uses
EP3510145A4 (en) 2016-09-06 2020-03-25 The Children's Medical Center Corporation IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
EP3385373A1 (en) 2017-04-05 2018-10-10 Centro de Neurociências e Biologia Celular Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
US11339405B2 (en) 2017-04-12 2022-05-24 Academia Sinica Kit and method for producing induced embryonic neural progenitors
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
WO2019053012A1 (en) 2017-09-13 2019-03-21 Biontech Rna Pharmaceuticals Gmbh RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS
JP2021502101A (ja) 2017-11-10 2021-01-28 ハワード ヒューズ メディカル インスティチュート 修飾されたリガンド依存性イオンチャネルおよび使用の方法
WO2019099552A1 (en) 2017-11-14 2019-05-23 The J. David Gladstone Institutes Methods of generating retinal pigment epithelium (rpe)
US11058729B2 (en) 2018-01-25 2021-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Exosomes and miRNA to treat glaucoma
KR102874471B1 (ko) 2018-03-05 2025-10-31 매사추세츠 아이 앤드 이어 인퍼머리 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법
WO2020012164A1 (en) 2018-07-13 2020-01-16 Ucl Business Ltd Glucocerebrosidase gene therapy
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
MX2021003663A (es) 2018-09-28 2021-05-28 Harvard College Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.
CN113164625B (zh) * 2018-09-28 2026-04-14 哈佛大学的校长及成员们 用于基因表达的突变体反向四环素反式激活因子
WO2021183825A1 (en) 2020-03-12 2021-09-16 California Institute Of Technology Adeno-associated viral capsids with expanded sizes
AU2021236391A1 (en) 2020-03-13 2022-09-29 Capricor, Inc. Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms
US20210324414A1 (en) 2020-04-16 2021-10-21 Massachusetts Institute Of Technology Compositions and methods for sequestering viruses
MX2023012722A (es) 2021-04-27 2023-11-08 Massachusetts Gen Hospital Capsides de aav y usos de las mismas.
US20240325568A1 (en) 2021-07-20 2024-10-03 The Broad Institute, Inc. Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
JP2025511883A (ja) 2022-04-06 2025-04-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 中枢神経系の加齢を逆行させること

Also Published As

Publication number Publication date
JP2025032120A (ja) 2025-03-11
US20240316148A1 (en) 2024-09-26
MX2021003663A (es) 2021-05-28
JP7593639B2 (ja) 2024-12-03
US12409207B2 (en) 2025-09-09
EP3856226B1 (en) 2026-02-18
US20260014229A1 (en) 2026-01-15
JP2022511373A (ja) 2022-01-31
AU2019347666A1 (en) 2021-03-25
IL281470B2 (en) 2025-08-01
US12414982B2 (en) 2025-09-16
IL281470B1 (en) 2025-04-01
AU2025283586A1 (en) 2026-01-22
WO2020069373A1 (en) 2020-04-02
EP3856226A1 (en) 2021-08-04
EP3856226C0 (en) 2026-02-18
US12582698B2 (en) 2026-03-24
KR20210068485A (ko) 2021-06-09
BR112021004670A2 (pt) 2021-06-01
AU2019347666B2 (en) 2025-10-02
IL281470A (en) 2021-04-29
CN113453702A (zh) 2021-09-28
US20240261370A1 (en) 2024-08-08
US20230338468A1 (en) 2023-10-26
US20260061028A1 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
US12582698B2 (en) Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) Cellular reprogramming to reverse aging and promote organ and tissue regeneration
JP7556092B2 (ja) 遺伝子編集のための組成物および方法
JP7589997B2 (ja) 遺伝子の発現のための変異体リバーステトラサイクリントランスアクチベーター
CN111727251B (zh) 用于治疗常染色体显性色素性视网膜炎的材料和方法
CN110582570A (zh) 用于治疗前蛋白转化酶枯草杆菌蛋白酶/Kexin 9型(PCSK9)相关的病症的组合物和方法
CN111836892A (zh) 用于治疗2a型乌谢尔综合征的材料和方法
WO2019116349A1 (en) Materials and methods for treatment of autosomal dominant cone-rod dystrophy
US20250099614A1 (en) Nucleic acid encoded transcription factor inhibitors
US20250325628A1 (en) Reversing aging of the central nervous system
WO2017131238A1 (ja) 未分化性低減による多能性幹細胞の分化促進法
JP2023544264A (ja) 核酸構築物、ウイルスベクター及びウイルス粒子
US20250170273A1 (en) Therapeutic factors for the treatment of polyq diseases
US20250127812A1 (en) Compositions and methods for engineering stable tregs
Pierattini SINEUP lncRNAs: from molecular mechanism to therapeutic application.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250603

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251001

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251202

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251202